N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies

Ming Lung Ho; Wei Ke Kuo; Lichieh J. Chu; I. Hsin Yeh; Chung Wei Fan; Hsin I. Chang; Cho Li Yuan; Ting Yu Chou; Hoang Yang Chen; Shih Wei Yang; Liang Che Chang; Minzhen Luo; Timothy H. Wu; Yi Feng I. Chang; Chia Jung Yu; Chung Ching Hua; Wailap V. Ng

doi:10.21873/anticanres.13842

N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies

Ming Lung Ho, Wei Ke Kuo, Lichieh J. Chu, I. Hsin Yeh, Chung Wei Fan, Hsin I. Chang, Cho Li Yuan, Ting Yu Chou, Hoang Yang Chen, Shih Wei Yang, Liang Che Chang, Minzhen Luo, Timothy H. Wu, Yi Feng I. Chang, Chia Jung Yu, Chung Ching Hua, Wailap V. Ng^*

^*Corresponding author for this work

Department of Biotechnology and Laboratory Science in Medicine

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background/Aim: The aim of this study was to evaluate N-acetylgalactosamine-6-sulfatase (GALNS) as a new biomarker candidate for detecting lung cancer. Glycodelin or PAEP, the serum levels of which are known to be elevated in lung and other cancers, served as a benchmark for comparison. Patients and Methods: A total of 170 serum samples from healthy controls and patients with pneumonia, lung cancer, breast cancer, colon cancer, liver cancer, and head and neck cancer were analyzed for the levels of GALNS and PAEP by ELISA. Results: The median serum levels of GALNS and PAEP in all cancer types as well as pneumonia patients were significantly higher than those of the healthy controls. Conclusion: In addition to previously known cancers, the median serum levels of PAEP were also found to be higher in liver and head and neck cancer patients. GALNS and PAEP are promising general biomarkers for multiple cancers and deserve further evaluation.

Original language	English
Pages (from-to)	6317-6324
Number of pages	8
Journal	Anticancer Research
Volume	39
Issue number	11
DOIs	https://doi.org/10.21873/anticanres.13842
State	Published - 2019

Keywords

Biomarkers
GALNS
Glycodelin
PAEP

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.13842

Cite this

Ho, M. L., Kuo, W. K., Chu, L. J., Yeh, I. H., Fan, C. W., Chang, H. I., Yuan, C. L., Chou, T. Y., Chen, H. Y., Yang, S. W., Chang, L. C., Luo, M., Wu, T. H., Chang, Y. F. I., Yu, C. J., Hua, C. C., & Ng, W. V. (2019). N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies. Anticancer Research, 39(11), 6317-6324. https://doi.org/10.21873/anticanres.13842

@article{51e4c160ae3b4f6998e3d8f228ae16af,

title = "N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies",

abstract = "Background/Aim: The aim of this study was to evaluate N-acetylgalactosamine-6-sulfatase (GALNS) as a new biomarker candidate for detecting lung cancer. Glycodelin or PAEP, the serum levels of which are known to be elevated in lung and other cancers, served as a benchmark for comparison. Patients and Methods: A total of 170 serum samples from healthy controls and patients with pneumonia, lung cancer, breast cancer, colon cancer, liver cancer, and head and neck cancer were analyzed for the levels of GALNS and PAEP by ELISA. Results: The median serum levels of GALNS and PAEP in all cancer types as well as pneumonia patients were significantly higher than those of the healthy controls. Conclusion: In addition to previously known cancers, the median serum levels of PAEP were also found to be higher in liver and head and neck cancer patients. GALNS and PAEP are promising general biomarkers for multiple cancers and deserve further evaluation.",

keywords = "Biomarkers, GALNS, Glycodelin, PAEP",

author = "Ho, {Ming Lung} and Kuo, {Wei Ke} and Chu, {Lichieh J.} and Yeh, {I. Hsin} and Fan, {Chung Wei} and Chang, {Hsin I.} and Yuan, {Cho Li} and Chou, {Ting Yu} and Chen, {Hoang Yang} and Yang, {Shih Wei} and Chang, {Liang Che} and Minzhen Luo and Wu, {Timothy H.} and Chang, {Yi Feng I.} and Yu, {Chia Jung} and Hua, {Chung Ching} and Ng, {Wailap V.}",

year = "2019",

doi = "10.21873/anticanres.13842",

language = "English",

volume = "39",

pages = "6317--6324",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "11",

}

Ho, ML, Kuo, WK, Chu, LJ, Yeh, IH, Fan, CW, Chang, HI, Yuan, CL, Chou, TY, Chen, HY, Yang, SW, Chang, LC, Luo, M, Wu, TH, Chang, YFI, Yu, CJ, Hua, CC & Ng, WV 2019, 'N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies', Anticancer Research, vol. 39, no. 11, pp. 6317-6324. https://doi.org/10.21873/anticanres.13842

TY - JOUR

T1 - N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies

AU - Ho, Ming Lung

AU - Kuo, Wei Ke

AU - Chu, Lichieh J.

AU - Yeh, I. Hsin

AU - Fan, Chung Wei

AU - Chang, Hsin I.

AU - Yuan, Cho Li

AU - Chou, Ting Yu

AU - Chen, Hoang Yang

AU - Yang, Shih Wei

AU - Chang, Liang Che

AU - Luo, Minzhen

AU - Wu, Timothy H.

AU - Chang, Yi Feng I.

AU - Yu, Chia Jung

AU - Hua, Chung Ching

AU - Ng, Wailap V.

PY - 2019

Y1 - 2019

N2 - Background/Aim: The aim of this study was to evaluate N-acetylgalactosamine-6-sulfatase (GALNS) as a new biomarker candidate for detecting lung cancer. Glycodelin or PAEP, the serum levels of which are known to be elevated in lung and other cancers, served as a benchmark for comparison. Patients and Methods: A total of 170 serum samples from healthy controls and patients with pneumonia, lung cancer, breast cancer, colon cancer, liver cancer, and head and neck cancer were analyzed for the levels of GALNS and PAEP by ELISA. Results: The median serum levels of GALNS and PAEP in all cancer types as well as pneumonia patients were significantly higher than those of the healthy controls. Conclusion: In addition to previously known cancers, the median serum levels of PAEP were also found to be higher in liver and head and neck cancer patients. GALNS and PAEP are promising general biomarkers for multiple cancers and deserve further evaluation.

AB - Background/Aim: The aim of this study was to evaluate N-acetylgalactosamine-6-sulfatase (GALNS) as a new biomarker candidate for detecting lung cancer. Glycodelin or PAEP, the serum levels of which are known to be elevated in lung and other cancers, served as a benchmark for comparison. Patients and Methods: A total of 170 serum samples from healthy controls and patients with pneumonia, lung cancer, breast cancer, colon cancer, liver cancer, and head and neck cancer were analyzed for the levels of GALNS and PAEP by ELISA. Results: The median serum levels of GALNS and PAEP in all cancer types as well as pneumonia patients were significantly higher than those of the healthy controls. Conclusion: In addition to previously known cancers, the median serum levels of PAEP were also found to be higher in liver and head and neck cancer patients. GALNS and PAEP are promising general biomarkers for multiple cancers and deserve further evaluation.

KW - Biomarkers

KW - GALNS

KW - Glycodelin

KW - PAEP

UR - http://www.scopus.com/inward/record.url?scp=85074729989&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13842

DO - 10.21873/anticanres.13842

M3 - Article

C2 - 31704862

AN - SCOPUS:85074729989

SN - 0250-7005

VL - 39

SP - 6317

EP - 6324

JO - Anticancer Research

JF - Anticancer Research

IS - 11

ER -

N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this